Eli Lilly and Company (NYSE:LLY) Given New $1,313.00 Price Target at Morgan Stanley

Eli Lilly and Company (NYSE:LLY) had its price target boosted by equities research analysts at Morgan Stanley from $1,290.00 to $1,313.00 in a report released on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley’s target price points to a potential upside of 26.87% from the stock’s previous close.

LLY has been the subject of a number of other research reports. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Berenberg Bank increased their price target on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. HSBC reissued a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Wolfe Research raised their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Finally, Loop Capital set a $950.00 price target on Eli Lilly and Company in a report on Monday, November 10th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,194.92.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $72.18 during midday trading on Thursday, hitting $1,034.94. The stock had a trading volume of 4,097,211 shares, compared to its average volume of 3,262,525. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock has a 50 day simple moving average of $1,054.31 and a 200-day simple moving average of $895.30. The company has a market capitalization of $978.41 billion, a PE ratio of 50.60, a P/E/G ratio of 0.76 and a beta of 0.39. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the prior year, the company earned $5.32 EPS. The firm’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently modified their holdings of LLY. Brighton Jones LLC lifted its stake in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. OneAscent Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 32.0% during the 2nd quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock worth $280,000 after buying an additional 87 shares during the last quarter. Sax Wealth Advisors LLC lifted its position in shares of Eli Lilly and Company by 14.3% during the 2nd quarter. Sax Wealth Advisors LLC now owns 689 shares of the company’s stock worth $537,000 after buying an additional 86 shares during the last quarter. Finally, Lattice Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 19.6% in the 2nd quarter. Lattice Capital Management LLC now owns 1,218 shares of the company’s stock valued at $949,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 beat and strong 2026 outlook — Lilly topped revenue and EPS estimates on surging sales of Mounjaro and Zepbound and gave upbeat 2026 guidance that underpinned the recent rally. Eli Lilly Beats Q4 Estimates But Shares Slide
• Positive Sentiment: Analysts remain constructive — at least one analyst kept an outperform rating and raised the price target (to $1,300), signaling continued confidence in Lilly’s multi‑year growth runway. Eli Lilly Beats Q4 Estimates But Shares Slide
• Positive Sentiment: Execution and capacity expansion support volume growth — MarketBeat’s sector coverage highlights Lilly’s manufacturing build‑out and vial strategy that helped offset U.S. pricing pressure by driving a big volume increase. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
• Neutral Sentiment: Ongoing capital investment — Lilly announced sizable new manufacturing spending (e.g., a $3.5B Pennsylvania facility), which supports longer‑term supply but is near‑term capex intensive. Eli Lilly to Invest Over $3.5 Billion in New Manufacturing Facility
• Neutral Sentiment: Pipeline and M&A activity diversify long‑term upside — deals (e.g., hearing‑loss and other collaborations) broaden optionality beyond GLP‑1s but will take time to materialize. Eli Lilly Is Getting Into the Hearing Loss Market
• Negative Sentiment: New low‑price competitor copy accelerates pricing fears — telehealth firm Hims & Hers announced a $49 copy of Wegovy, stoking concerns that cheaper entrants and pricing pressure could erode margins and force faster price competition across the GLP‑1 category. That news is a near‑term catalyst for the pullback. Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
• Negative Sentiment: Profit‑taking and volatility after a huge run — after the stock surged on the beat and guidance (reclaiming ~$1T market cap), some investors are locking gains; analysts and outlets warn a pullback is possible given the stock’s run and valuation sensitivity to GLP‑1 pricing assumptions. Why Eli Lilly Stock Just Dropped

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.